В начале текущего года стало известно, что Samsung разрабатывает фирменную оболочку One UI 2.5 для своих смартфонов. Новое программное обеспечение дебютировало с Galaxy Note20, Galaxy Z Flip 5G и серией Galaxy Tab S7. В день запуска этих устройств южнокорейский техногигант выпустил One UI 2.5 для линейки Galaxy S20 и Galaxy Z Flip. Теперь развёрнут выпуск обновления One UI 2.5 для серий Galaxy S10 и Galaxy Note10.
Файл с обновлением имеет объём 963,49Мб и также включает исправления системы безопасности Android от сентября 2020 года. Обновление One UI 2.5 активирует режим Wireless DeX, который дебютировал в сериях Galaxy Note20 и Galaxy Tab S7. Он позволяет отображать экран DeX UI вашего смартфона по беспроводной сети на любом телевизоре с функцией Miracast. Появился быстрый переключатель для режима Wireless DeX и параметры для настройки масштабирования экрана и размера шрифта.
Прошивка также включает улучшенный режим Pro Video Mode в приложении камеры, более простой способ обмена учётными данными Wi-Fi с другими устройствами Galaxy и возможность поиска видео YouTube в приложении клавиатуры. Режим Pro Video позволяет выбрать разрешение видео и частоту кадров, микрофон (передний, задний, оба, USB или Bluetooth).
Другие функции, которые являются частью обновления, — это поддержка стикеров Bitmoji для режима Always On Display, разделённая клавиатура в альбомном режиме, предварительная конфигурация сообщений SOS и возможность отправлять сообщения о местоположении SOS каждые 30 минут в течение 24-х часов.
Прошивка также содержит другие исправления ошибок, улучшения безопасности и общей производительности устройства.
Если вы имеете прошлогодний флагман, но ещё не получили это обновление, не беспокойтесь. Распространение прошивки неравномерно запускается по разным странам и регионам. Кроме того, по традиции первыми получают заветный файл владельцы аппаратов с фирменными процессорами Exynos, а чуть позже они приходят на коммуникаторы с вычислительной платформой Qualcomm Snapdragon, сообщает профильный ресурс SamMobile.
Galaxy S10 and Galaxy Note10 series starts getting One UI 2.5 update
6 months ago Samsung developed One UI 2.5 for its smartphones. The new software debuted with the Galaxy Note 20, Galaxy Z Flip 5G, and the Galaxy Tab S7 series. On the launch day of these devices, the South Korean firm released One UI 2.5 to the Galaxy S20 series and the Galaxy Z Flip. Now, the company has started rolling out the One UI 2.5 update to the Galaxy S10 and Galaxy Note10 series.
The Galaxy S10 has started receiving the One UI 2.5 update in Germany. It’s a 963,49Mb update that carries firmware version G973FXXU8DTH7. The firmware versions for the Galaxy S10e and the Galaxy S10+ are G970FXXU8DTH7 and G975FXXU8DTH7, respectively.
The new software update brings along the September 2020 Android security patch. The One UI 2.5 update includes Wireless DeX, which debuted on the Galaxy Note 20 and the Galaxy Tab S7 series. It lets you mirror your smartphone’s DeX UI screen wirelessly to any TV that features Miracast. There is now a quick setting toggle for the Wireless DeX mode and options to adjust screen zoom and font size.
The new update also comes with an enhanced Pro Video Mode in the camera app, an easier way to share Wi-Fi credentials with other Galaxy devices, and the ability to search for YouTube videos in the keyboard app. The Pro Video Mode allows the selection of video resolution and frame rate, mic selection (front, rear, all, USB, or Bluetooth). The Galaxy S10 series also gets Single Take duration selection (5 seconds to 15 seconds).
Other features that are a part of the new software update for the Galaxy S10 are support for Bitmoji Stickers for the Always On Display mode, split keyboard in the landscape mode, SOS message pre-configuration, and the ability to send SOS location messages every 30 minutes for 24 hours. Bug fixes, security enhancement, and performance improvements are also a part of the update.
If you’re a Galaxy S10e, Galaxy S10, or Galaxy S10+ user in Germany, you can check for the update by navigating to the phone’s Settings menu, selecting Software update, and tapping Download and install. You can also download the new firmware files from our firmware section. Other regions could soon get the update for the Galaxy S10, Galaxy S10+, Galaxy S10e and the Galaxy Note10 series.
The latest iteration of Samsung’s custom mobile OS, One UI 2.5, is now rolling out to the international variants of the Galaxy Note 10 and Galaxy Note 10+, as well as the Galaxy Note 10+ 5G. It hence appears that the entirety of last year’s flagship range is now transitioning to this particular implementation of Android 10. And yes, that includes the Galaxy Note 10 Lite.
Samsung Group продолжает расширять свой фармацевтический бизнес, инвестируя порядка $2 миллиардов в строительство завода по производству лекарств, который станет крупнейшим такого рода объектом в мире. Предприятие должно быть запущено в 2022-м году и призвано снизить зависимость развитых стран (прежде всего регионов Северной Америки и Европы) от поставок лекарств из Китая и Индии, где в последнее время наблюдались проблемы из-за остановки ряда заводов-производителей ингридиентов.
По сообщению The Wall Street Journal (WSJ), подразделение Samsung BioLogics делает ставку на дальнейший рост рынка сложных биологических лекарственных препаратов благодаря изменениям в отрасли, связанным с пандемией коронавирусной инфекции.
Завод по синтезу лекарственных препаратов, получивший название Super Plant, станет 4-м предприятием Samsung BioLogics Co. Его площадь составит примерно 230.000 квадратных метров. Это больше, чем все 3 ныне существующих предприятия вместе взятых, что превышает площадь парижского Лувра.
Ведущий южнокорейский чеболь намерен воспользоваться беспрецедентным ростом спроса на лекарства в мире, отмечает WSJ.
Samsung BioLogics производит биопрепараты для целого ряда международных фармацевтических гигантов, включая Bristol-Myers Squibb Co., и Roche Holding Ltd.
Глава подразделения Ким Тэ-хан сказал в интервью WSJ, что изначально планировалось построить завод гораздо меньшего размера, однако пандемия коронавируса создала новую категорию продуктов - средства для лечения COVID-19, побудив разработчиков лекарств и национальные правительства искать новые мощности для производства.
"COVID-19 даёт нам больше возможностей, чем кризис", - отметил Ким Тэ-хан, который возглавляет Samsung BioLogics с 2011 года и, как сообщается, продвигал идею строительства такого предприятия в руководстве Samsung Group.
WSJ: Samsung’s Drugmaking Future Includes a $2 Billion ‘Super Plant’ Bigger Than the Louvre
Samsung’s drug-manufacturing arm is betting that the already-booming market for biologic drug ingredients will only get hotter, thanks to industry shifts sparked by the coronavirus pandemic.
Key to that bet is a nearly $2 billion drugmaking plant that, when completed in 2022, will be the largest of its kind in the world. Dubbed the “Super Plant,” Samsung Biologics Co.’s fourth factory will have around 230,000 square meters, or nearly 2.5 million square feet, of floor space, making it bigger than the company’s three existing plants combined and slightly larger than the Louvre.
Samsung’s goal is to capture what the company has said is an unprecedented increase in demand spurred by the pandemic, and to take advantage of the simultaneous reckoning it is creating for global drug production.
Demand for new and increasingly complex medicines has skyrocketed since the pandemic began. The situation has exposed how reliant conventional drug production has become on China and India, potentially threatening supply chains. That uptick in demand has been beneficial to Samsung Biologics, which is based here and specializes in the production of complex medicines for rare diseases. This year, the business has expanded into potential Covid-19 antibody treatments.
The firm makes biologic drugs for some of the world’s largest pharmaceutical companies, including Bristol-Myers Squibb Co. and Roche Holding Ltd.
The company’s chief executive, Kim Tae-han, told The Wall Street Journal the new plant was originally planned to be far smaller. But he pushed for a bolder expansion this year after seeing how the pandemic created a new product category, Covid-19 treatments, and prompted drug developers and national governments alike to find new manufacturing sources.
“Covid-19 is giving us more opportunity than crisis,” said Mr. Kim, who has led Samsung Biologics since 2011 after helping pitch the venture to Samsung’s top leaders.
Samsung Biologics has seen manufacturing orders nearly triple to $1.5 billion in its most recent quarter from the prior year. A recent deal with GlaxoSmithKline PLC accounts for $370 million over the next two years, or about 60% of last year’s sales. Mr. Kim said the company is nearing maximum use of its three plants more quickly than expected, and the new facility will help it meet demand.
Samsung Biologics executives say they are in conversations with other biopharmaceutical companes to manufacture Covid-19 antibodies but declined to name the firms.
Before the pandemic hit, drugmakers were already tapping contract manufacturers like Samsung Biologics to produce complex treatments, especially as biopharmaceuticals become a larger fraction of drug sales world-wide.
After a drug is first developed, contract manufacturers step in to make biologic compounds, which are complex medicines derived from living cells. This work can entail research and development, clinical trials or commercial rollouts.
Biotechnology currently makes up 30% of global sales of prescription and over-the-counter medication, and these drugs are expected to expand by another 5 percentage points by 2026, according to research firm EvaluatePharma. Five years ago, the sector represented less than a quarter of total sales.
Drug developers, racing to develop antibodies and vaccines to treat the coronavirus, have also been nudged to reconsider where and how they manufacture their treatments. The U.S. government has pushed to produce more drugs domestically and lessen dependence on foreign production, even planning to loan Eastman Kodak Co. $765 million before the deal fell through last month.
More demand has also come from pharmaceutical companies alarmed by supply-chain disruptions abroad in the past year. Firms once inclined to consolidate manufacturing deals to save money are now willing to pay higher costs to ensure they have multiple sources for the compounds they need.
“Essentially what’s happening is everyone is scrambling for space” at contract manufacturing sites because of new coronavirus orders, said Eric Langer, president of Rockville, Md.-based BioPlan Associates, a research and marketing firm. “A lot of the companies, even pre-pandemic, were just fully booked.”
Samsung Biologics is one of several dozen affiliates in South Korea’s largest conglomerate, best known for smartphones and consumer electronics. Samsung’s business empire also includes theme parks and life insurance, but its push into biopharmaceuticals is relatively recent.
Founded in 2011, Samsung Biologics went public five years later and first turned a profit in 2015.
Samsung Biologics is already one of the world’s largest contract-drug makers based on capacity, and its Songdo complex is the largest single biologic drugmaking facility in the world, according to market tracker BioPlan Associates. The company’s Europe-based rivals, Lonza Group AG and Boehringer-Ingelheim GmbH, also plan to expand operations.
Samsung Biologics plans to expand substantially over the next decade. It is pursuing a deal for a second campus near its current complex in Songdo, a western suburb of Seoul, which could house up to four more plants.
Mr. Kim said the company’s reasons for keeping production out of China remain economic, not political, pointing to China’s relatively uncertain conditions for foreign businesses. More than 70% of global contract manufacturing demand for biopharmaceuticals comes from the U.S. and Western Europe, he said.
Mr. Kim sees Samsung Biologics’ growth as part of the growing shift in biopharmaceutical production and innovation toward Asia, mirroring other industries such as shipbuilding and chemicals. Most of the biopharmaceutical business is in the West, he added.
“Maybe 10 years later, 20 years later, it can be 50/50,” Mr. Kim said.
